From Benzinga’s All-Access Conference: AIM ImmunoTech CEO, Thomas Equels Says Co Has Multiple Oncology Clinical Trials In The Process Currently
https://www.youtube.com/watch?v=FHUuAwo4G1g
From Benzinga’s All-Access Conference: AIM ImmunoTech CEO, Thomas Equels Begins Presenting
https://www.youtube.com/watch?v=FHUuAwo4G1g
AIM ImmunoTech’s Ampligen Safety Data Presented At Eighth European Scientific Working Group On Influenza
AIM ImmunoTech Inc. (NYSE:AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on
AIM ImmunoTech CEO To Participate In Two Upcoming Investor Conferences
AIM ImmunoTech Inc. (NYSE:AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.
BioFlorida Conference
Mr. Equels will be participating in
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell
• NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
AIM ImmunoTech Inc (NYSE:AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal…
AIM ImmunoTech Announces Clinical Trial Agreement For A Phase 2a Human Challenge Trial Of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
AIM ImmunoTech Inc. (NYSE:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential
AIM ImmunoTech Files Provisional Patent Application For Ampligen As Early-Onset Intranasal Therapy That May Also Confer Enhanced Immunity To A Wide Range Of Respiratory Viruses
AIM ImmunoTech Inc. (NYSE:AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
AIM ImmunoTech Inc (NYSE:AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for…
AIM ImmunoTech Says FDA Meeting Request Has Been Deemed Sufficient For Transfer To FDA’s Division Of Neurology
AIM ImmunoTech Inc. (NYSE:AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion